The Potential of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer
From Mechanism to Action

MONDAY, 8 AUGUST 2022 | 18:00 – 19:00 CET

MESSE WIEN EXHIBITION & CONGRESS CENTER | MESSEPLATZ 1
A-1021 VIENNA, AUSTRIA | ROOM: STRAUSS 3

MODERATOR
Hossein Borghaei, DO, MS
Professor, Department of Hematology/Oncology
Chief, Division of Thoracic Medical Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States

PANELISTS
Antonio Passaro, MD, PhD
Medical Oncologist
Division of Thoracic Oncology
IRCCS European Institute of Oncology
Milan, Italy

Ticiana Leal, MD
Associate Professor
Department of Hematology and Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia, United States

For more information and to register, visit:
www.medscape.org/symposium/nsclc-adc
TARGET AUDIENCE
This activity is intended for an international audience of hematology/oncology specialists, pathologists, pulmonologists, and other members of the oncology care team.

LEARNING OBJECTIVES
Upon completion of this activity, participants will:

- Have increased knowledge regarding the
  - Mechanism of action of antibody-drug conjugates (ADCs)
  - Latest clinical trials investigating ADCs in non-small cell lung cancer (NSCLC)

- Have greater competence related to
  - Diagnosing molecular alterations that are amenable to treatment with ADCs

- Demonstrate greater confidence in their
  - Understanding of the implications of the latest clinical evidence for ADCs in NSCLC

ACCREDITATION STATEMENT
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

AGENDA
18:00
Welcome and Introduction
Hossein Borghaei, DO, MS

18:03
Mechanism of Action and Targets of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer
Antonio Passaro, MD, PhD

18:18
Antibody-Drug Conjugates in Non-Small Cell Lung Cancer. What Do the Data Show?
Hossein Borghaei, DO, MS

18:35
Antibody-Drug Conjugates in the Clinic: Challenges and Perspectives
Ticiana Leal, MD

18:50
Audience Q&A
All Faculty

18:59
Concluding Remarks
Hossein Borghaei, DO, MS

Light snacks offered by Medscape

For more information and to register, visit:
www.medscape.org/symposium/nsclc-adc